<article id="info" class="slide" data-ag-name="Information">
  <h1>Important Information<sup class="footnote-link">1</sup></h1>
  <div class="text">
    <div class="section">
      <div class="info-heading">Contraindications</div>
      <ul>
        <li>Ocular or periocular infection</li>
        <li>Active intraocular inflammation</li>
        <li>Hypersensitivity to aflibercept or to any ingredient in the formulation</li>
      </ul>
    </div>
    <div class="section">
      <div class="info-heading">Other relevant warnings and precautions</div>
      <ul>
        <li>Potential risk of arterial thromboembolic events</li>
        <li>Risk of immunogenicity and hypersensitivity reactions including anaphylaxis</li>
        <li>Risk of endophthalmitis, retinal detachment, retinal tear and cataract</li>
        <li>Risk of increased intraocular pressure (IOP)</li>
        <li>As with other anti-VEGF treatments, treatment should be withheld and resumed only when considered appropriate in cases of: patients with an IOP of â‰¥30 mmHg, 
        <br>within the previous or next 28 days in the event of a performed or planned intraocular surgery, a retinal break</li>
        <li>Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last injection</li>
        <li>Should not be used during pregnancy</li>
        <li>Not recommended during breastfeeding</li>
        <li>Do not drive or use machinery until vision function recovers sufficiently</li>
        <li>Has not been studied in hepatic and renal impairment, in pediatric patients or as therapy administered to both eyes concurrently or consecutively</li>  
      </ul>
    </div>
    <div class="section">
      <div class="info-heading">For more information</div>
      <p>Please consult the product monograph at bayer.ca/files/EYLEA-PM-ENG.pdf relating to adverse reactions, drug interactions and dosing information which have not been discussed in this piece.</p>
      <p>The product monograph is also available by calling Bayer Medical Information at 1-800-265-7382.</p>
    </div>    
  </div>
</article>